Fermion’s priority and passion is to offer its clients quick-to-market HPAPI development solutions
The HPAPI market is on the rise with a large industry interest in developing ADCs and other smart drug delivery solutions with highly potent payloads. Drug developers and manufacturers are also inclined to classify their new molecular entities to a higher containment category than before to ensure adequate worker protection. Consequently, drug developers turn to manufacturers that have the capacity and capabilities to handle HPAPIs and they need to ensure these manufacturers are committed to investing in these capabilities to support the growing demand in the long run.
Fermion has recently announced the expansion of its largest manufacturing site in Hanko, Southern Finland. Fermion’s President Arto Toivonen said: 'The expansion lifts Fermion to a new level in the global arena of API and especially HAPI manufacturing, improving Fermion’s capability to meet increasing demand. Fermion will continue to ensure high quality and delivery reliability of its products. The new unit alone will be able to produce 100 metric tons of HPAPI per year, increasing the total production capacity of Fermion to over 400 metric tons API/year. Fermion’s scale of HPAPI development and production will now be complete with capabilities from grams to tons.'
Fermion’s priority and passion is to offer its clients quick-to-market HPAPI development solutions, with the safety of its staff and the patients guaranteed and the integrity of the environment maintained. The video is all about our one-stop shop HPAPI concept offering the full range of HPAPI services saving time and costs.